PT3071595T - Anticorpo anti calicreína-2 humanizado - Google Patents

Anticorpo anti calicreína-2 humanizado

Info

Publication number
PT3071595T
PT3071595T PT14814696T PT14814696T PT3071595T PT 3071595 T PT3071595 T PT 3071595T PT 14814696 T PT14814696 T PT 14814696T PT 14814696 T PT14814696 T PT 14814696T PT 3071595 T PT3071595 T PT 3071595T
Authority
PT
Portugal
Prior art keywords
kallikrein
antibody
humanised anti
humanised
anti kallikrein
Prior art date
Application number
PT14814696T
Other languages
English (en)
Inventor
Strand Sven-Erik
SJÖSTRÖM Kjell
Oskar Vilhelmsson Timmermand Pär
Thuy Tran Amanda
Juhani Lamminmäki Urpo
Original Assignee
Fredax Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1320408.6A external-priority patent/GB2520353A/en
Priority claimed from GB201401973A external-priority patent/GB201401973D0/en
Application filed by Fredax Ab filed Critical Fredax Ab
Publication of PT3071595T publication Critical patent/PT3071595T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
PT14814696T 2013-11-19 2014-11-19 Anticorpo anti calicreína-2 humanizado PT3071595T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1320408.6A GB2520353A (en) 2013-11-19 2013-11-19 Antibody polypeptides and uses thereof
GB201401973A GB201401973D0 (en) 2014-02-05 2014-02-05 Antibody polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
PT3071595T true PT3071595T (pt) 2019-06-11

Family

ID=52114029

Family Applications (1)

Application Number Title Priority Date Filing Date
PT14814696T PT3071595T (pt) 2013-11-19 2014-11-19 Anticorpo anti calicreína-2 humanizado

Country Status (22)

Country Link
US (3) US10100125B2 (pt)
EP (2) EP3553088A1 (pt)
JP (3) JP6599859B2 (pt)
KR (3) KR102442738B1 (pt)
CN (2) CN105980404B (pt)
AU (3) AU2014351611B2 (pt)
BR (1) BR112016011025B1 (pt)
CA (1) CA2930493A1 (pt)
CY (1) CY1121900T1 (pt)
DK (1) DK3071595T3 (pt)
ES (1) ES2728515T3 (pt)
HR (1) HRP20191095T1 (pt)
HU (1) HUE043875T2 (pt)
IL (3) IL297678A (pt)
LT (1) LT3071595T (pt)
MX (2) MX2016006561A (pt)
PL (1) PL3071595T3 (pt)
PT (1) PT3071595T (pt)
RS (1) RS58831B1 (pt)
RU (1) RU2687163C1 (pt)
SI (1) SI3071595T1 (pt)
WO (1) WO2015075445A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE043875T2 (hu) * 2013-11-19 2019-09-30 Fredax Ab Humanizált, kallikrein-2 elleni antitest
MY192513A (en) 2014-03-28 2022-08-24 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
PL3253800T3 (pl) 2015-03-27 2021-08-23 Opko Diagnostics, Llc Standardy antygenów prostaty i ich zastosowanie
WO2017087826A1 (en) * 2015-11-18 2017-05-26 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
MX2019006448A (es) 2016-12-01 2020-02-05 Regeneron Pharma Anticuerpos anti-pd-l1 radiomarcados para imagenes de inmuno-pet.
JP7167041B2 (ja) 2017-02-10 2022-11-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体
JP7071994B2 (ja) * 2017-03-30 2022-05-19 プロガストリン、エ、カンセル、エス、アー エル、エル 前立腺がんを治療するための組成物および方法
CN110997013B (zh) 2017-07-24 2022-09-20 瑞泽恩制药公司 抗cd8抗体和其用途
CA3139806A1 (en) 2019-05-10 2020-11-19 Janssen Biotech, Inc. Macrocyclic chelators and methods of use thereof
AU2020322222A1 (en) * 2019-07-26 2022-03-24 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
WO2021019386A1 (en) * 2019-07-26 2021-02-04 Janssen Biotech, Inc. Anti-hk2 chimeric antigen receptor (car)
TW202210510A (zh) 2020-05-27 2022-03-16 美商健生生物科技公司 包含ｃｄ３抗原結合域之蛋白質及其用途
JP2023533857A (ja) * 2020-07-17 2023-08-04 ヤンセン バイオテツク，インコーポレーテツド 抗ｋｌｋ２抗体に対する抗イディオタイプ抗体
TW202233244A (zh) * 2020-11-10 2022-09-01 美商健生生物科技公司 巨環化合物及其使用方法
CN112608365B (zh) * 2020-12-22 2021-07-30 吉林省特医食品生物科技有限公司 一种减轻体重的发酵型小分子肽及其制备方法和应用
WO2022156798A1 (zh) * 2021-01-25 2022-07-28 成都康弘生物科技有限公司 一种抗体及其用途
EP4284446A2 (en) 2021-01-27 2023-12-06 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
US20230011134A1 (en) 2021-05-27 2023-01-12 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer
WO2023084397A1 (en) 2021-11-09 2023-05-19 Janssen Biotech, Inc. Macrocyclic compounds and diagnostic uses thereof
WO2023084396A1 (en) 2021-11-09 2023-05-19 Janssen Biotech, Inc. Macrocyclic compounds and methods of making the same
WO2023144723A1 (en) 2022-01-26 2023-08-03 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
JP2001503991A (ja) 1996-11-14 2001-03-27 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 転移性前立腺癌の検出方法
US7053042B1 (en) 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
AU3879200A (en) 1999-08-16 2001-03-13 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
EP1392360B1 (en) 2001-06-01 2011-11-30 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2003029427A2 (en) 2001-10-03 2003-04-10 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
AU2004209984B2 (en) 2003-01-31 2010-08-05 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
CN101094869A (zh) * 2004-08-03 2007-12-26 戴埃克斯有限公司 Hk1结合蛋白
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
MX2007009935A (es) * 2005-02-18 2007-10-10 Medarex Inc Anticuerpos monoclonales que carecen de residuos fucosilo contra antigeno membranal especifico de prostata (psma).
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
MX2009005776A (es) 2006-12-01 2009-06-10 Medarex Inc Anticuerpos humanos que se enlazan al cd 22 y sus usos.
EP2106262B1 (en) * 2006-12-22 2015-11-18 Phadia AB Novel prostate kallikrein allergen
EP2347038A4 (en) * 2008-10-14 2013-06-12 Janssen Biotech Inc METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
KR102362358B1 (ko) * 2011-10-28 2022-02-15 프레닥스 에이비 치료제 및 이의 용도
HUE043875T2 (hu) * 2013-11-19 2019-09-30 Fredax Ab Humanizált, kallikrein-2 elleni antitest

Also Published As

Publication number Publication date
LT3071595T (lt) 2019-05-10
BR112016011025A2 (pt) 2017-12-05
IL245617A0 (en) 2016-06-30
IL278493B2 (en) 2023-04-01
DK3071595T3 (da) 2019-07-01
KR102442738B1 (ko) 2022-09-15
HUE043875T2 (hu) 2019-09-30
US11230609B2 (en) 2022-01-25
JP2016540503A (ja) 2016-12-28
KR20220020406A (ko) 2022-02-18
EP3071595A1 (en) 2016-09-28
HRP20191095T1 (hr) 2019-09-20
CN112898431A (zh) 2021-06-04
EP3553088A1 (en) 2019-10-16
MX2016006561A (es) 2016-12-12
JP2022062048A (ja) 2022-04-19
KR20160096621A (ko) 2016-08-16
CA2930493A1 (en) 2015-05-28
CN105980404B (zh) 2021-01-12
RU2687163C1 (ru) 2019-05-07
RU2016124229A (ru) 2017-12-25
WO2015075445A1 (en) 2015-05-28
AU2020207775B2 (en) 2023-06-15
EP3071595B1 (en) 2019-03-20
JP6599859B2 (ja) 2019-10-30
PL3071595T3 (pl) 2019-09-30
BR112016011025B1 (pt) 2024-01-23
BR112016011025A8 (pt) 2018-01-30
KR20230132599A (ko) 2023-09-15
US20190169312A1 (en) 2019-06-06
SI3071595T1 (sl) 2019-08-30
RS58831B1 (sr) 2019-07-31
ES2728515T3 (es) 2019-10-25
US20220064333A1 (en) 2022-03-03
AU2014351611A1 (en) 2016-06-30
IL245617B (en) 2021-02-28
AU2023222879A1 (en) 2023-09-14
AU2014351611B2 (en) 2020-04-23
CN105980404A (zh) 2016-09-28
US10100125B2 (en) 2018-10-16
JP7051777B2 (ja) 2022-04-11
IL278493A (en) 2022-12-01
MX2021007006A (es) 2021-09-08
JP2020022470A (ja) 2020-02-13
IL297678A (en) 2022-12-01
US20160369009A1 (en) 2016-12-22
CY1121900T1 (el) 2020-10-14
AU2020207775A1 (en) 2020-08-06
KR102574537B1 (ko) 2023-09-06

Similar Documents

Publication Publication Date Title
IL245617A0 (en) Humanized antibody against kallikrein-2
IL269528A (en) Anti- FCRH5 antibodies
ZA201506568B (en) Anti-tnf-anti-il-17 bispecific antibodies
EP3083698A4 (en) Monoclonal anti-tk1 antibodies
GB201322583D0 (en) Antibodies
HK1220142A1 (zh) 抗體
GB201308658D0 (en) Antibodies
HK1220207A1 (zh) 人源化抗 抗體
GB201315486D0 (en) Antibodies
GB201300706D0 (en) Antibody
IL245488B (en) Anti- ccl17 antibodies
HK1217340A1 (zh) 針對 的單克隆抗體
HK1215714A1 (zh) -- -甲基***單克隆抗體
GB201318283D0 (en) Antibodies